Post Tagged with: "Gilead Sciences"

Gilead Sciences Says FDA Accepts New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy

April 21, 2014 at 8:20 pm

Gilead Sciences (GILD) says the FDA accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor forRead More

Biotechs Gain As Barron’s Identifies Opportunities Following Sell-Off

April 17, 2014 at 3:30 pm

Biotech stocks (SPSIBI) are higher Monday following a Barron’s article suggesting selected shares look attractive following a 27% selloff in the sector from February highs of near $4,400. Mentioned in the article are Amgen (AMGN), up 2.1% at $114.29 per share, Gilead Sciences (GILD) up 1.6% at $67.09, and CelgeneRead More